natgillin/translations-raw huggingface dataset:
is optionally substituted pyridinone, pyridyl, pyridyl-N-oxide, or pyrazolyl, provided that 
je po izboru supstituirani piridinon, piridil, piridil-N-oksid ili pirazolil, uz uvjet da
<400> 5 A process for preparing interleukin-2 for pharmaceutical use, comprising the steps of: (a) adding sodium dodecyl sulfate (SDS) to a composition comprising IL-2 with intramolecular disulfide bridges, to give a final SDS concentration of at least 500µg SDS per mg of IL-2; (b) removing any precipitated covalently-linked IL-2 multimers by gel filtration; and (c) reducing the SDS concentration to remove some but not all SDS from the composition, to give a composition that contains between 95-250µg SDS per mg of IL-2. 
Proces za pripremu interleukina-2 za farmaceutsku uporabu, naznačen time, da se sastoji od stupnjeva: (a) dodavanje natrij dodecil sulfata (SDS - Sodium Dodecyl Sulfate) sastavu koji sadrži IL-2 s intramolekularnim disulfidnim vezama, da dade konačnu koncentraciju SDS od barem 500ug SDS po mg IL-2; (b) odstranjivanje bilo kojeg od istaloženih kovalentno vezanih IL-2 multimera pomoću gel filtracije; i (c) smanjivanje koncentracije SDS da se odstrani nešto, ali ne sav SDS iz sastava, da dade sastav koji sadrži između 95-250ug SDS po mg IL-2.
determining whether the or each mutant GPCR has increased conformational stability with respect to binding the selected ligand compared to the conformational stability of the parent GPCR with respect to binding that ligand, by measuring denaturation as manifest by loss of ligand binding ability, under denaturing conditions such as heat, a detergent, a chaotropic agent or an extreme of pH, and 
(c) određivanje je li ta ili svaka mutacija GPCR-a povećala konformacijsku stabilnost u odnosu na vezanje odabranog liganda u usporedbi s konformacijskom stabilnosti izvornog GPCR-a u odnosu na sposobnost vezanja tog liganda, i to na temelju mjerenja denaturacije koja se očituje gubitkom sposobnosti vezanja liganada, pod uvjetima denaturacije kao što su zagrijavanje, deterdžent, kaotrop ili ekstremni pH, te
Compound (d) obtained from Step 3 is dissolved in MeOH and treated with 10 eq 1M aqueous NaOH solution. 
Spoj (d) dobiven u Koraku 3 otopi se u MeOH, te obradi s 10 ekv.
The oral suspension of the invention is characterized by a lack of bitter taste. 
Oralna suspenzija izuma je karakterizirana manjkom gorkog okusa.
The pharmaceutical composition according to claim 1, further comprising at least one additional peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO 3 to SEQ ID NO 20. 
HR P20190202 T1 HR P20190202 T1 PATENTNI ZAHTJEVI 1. = Peptid koji se sastoji od sekvence aminokiselina prema SEQ ID br. 10.
A cyclic peptide comprising formula IIa, IIb, or IIc or or a pharmaceutically acceptable salt thereof, wherein: 
Ciklični peptid koji sadrži formulu Ila, IIb, ili lic ili iš se zo rk o an i RA
is hydrogen, alkyl or acyl; or a pharmaceutically acceptable salt or a stereoisomer thereof. 
R5 je vodik, alkil ili acil; ili njegova farmaceutski prihvatljiva sol.
Process according to claim 39, wherein the caramelised feedstock is subjected to a filtration step. 
Postupak prema zahtjevu 39, naznačen time, što karamelizirana sirovina se podvrgava koraku filtracije.
In another exemplary composition provided by the present invention, a nasal spray formulation containing azelastine hydrochloride was prepared using hypromellose as a thickener and sucralose and menthol as taste-masking agents: 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je navedeni pripravak formuliran kao tekuća formulacija u obliku nazalnog spreja ili nazalnih kapi.
The method of item 33, wherein the dermatitis is allergic dermatitis, atopic dermatitis, dermatitis due to chemical exposure, or radiation-induced dermatitis. 
Farmaceutski pripravak za uporabu prema zahtjevu 33, naznačen time da je dermatitis alergijski dermatitis, atopijski dermatitis, dermatitis zbog kemijske izloženosti, ili dermatitis izazvan zračenjem.
A non-therapeutic method for repairing defects in the skin surface for cosmetic enhancement comprising applying an isolated compound selected from cycloastragenol, astragenol, astragaloside IV, astragaloside IV 16-one, cycloastragenol 6-B-D-glucopyranoside, and cycloastragenol 3-B-D-xylopyranoside. 
Farmaceutski pripravak, naznačen time što sadrži topikalnu formulaciju izdvojenog spoja koji se bira između cikloastragenola, astragenola, astragalozid IV 16-ona, cikloastragenol 6-B-d-glukopiranozida i cikloastragenol 3-B-d-ksilopiranozida.
lmmunosuppressive agents have been shown to be useful in a wide variety of autoimmune and chronic inflammatory diseases including transplant rejection, multiple sclerosis, lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma, myocarditis, atopic dermatitis, type-1 diabetes, atherosclerosis, glomerulonephritis, lymphocytic leukemias, lymphomas, multiorgan failure, sepsis, pneumonia, etc. 
Pokazalo se da su imunosupresivi korisni kod širokog raspona autoimunih i kroničnih upalnih bolesti, uključujući odbacivanje presatka, multiplu sklerozu, eritematozni lupus, reumatoidni artritis, upalnu bolest crijeva, psorijazu, astmu, miokarditis, atopični dermatitis, dijabetes tip 1, aterosklerozu, glomerulonefritis, limfocitne leukemije, limfome, zatajenje više organa, sepsu, pneumoniju itd.
polysorbate 80 at a final concentration of 0.01% to 0.05% polysorbate 80 weight/volume of the formulation and 
(ii) polisorbat 80 u konačnoj koncentraciji od 0,01% do 0,05% polisorbata 80, težinski, po volumenu formulacije i
storing the G-CSF composition obtained in step (b) in the frozen state over a period of at least one month; 
(c) pohranjivanje G-CSF-sastava dobivenog u koraku (b) u zamrznutom stanju na vremenski period od najmanje mjesec dana; 1
Thus the invention provides a process for preparing an influenza vaccine from influenza virus that has been grown in a culture of a mammalian cell line, comprising a step in which the vaccine and/or the culture is tested for the presence of an infectious agent that can grow in said cell line but that does not grow in embryonated hen eggs, wherein the infectious agent is selected from the group consisting of: Pneumovirinae; mammalian Reoviridae; Birnaviridae; Rubulaviruses of the Paramyxoviridae family; Coronaviridae; Rhinoviruses of the Picornaviridae family; Varicella Zoster virus; BK polyomavirus, JC polyomavirus; Echoviruses; Coxsackieviruses of the Enteroviruses of the Picornaviridae family; Rotavirus; Porcine picornaviruses; Parvovirus; Circovirus; and Chlamydia bacteria. 
PATENTNI ZAHTJEVI L ll. Postupak za pripremanje cjepiva protiv gripe iz virusa gripe izraslog u kulturi MDCK stanične linije, koji sadrži stupanj u kojem se uzgojeni virus i/ili cjepivo i/ili kultura testira na prisutnost infekcijskog agensa koji može rasti u navedenoj staničnoj liniji, ali koji ne raste u embriju kokošjih jaja, naznačen time, da je navedeni infekcijski agens jedan ili više od sljedećih patogena: Reoviridae kod sisavaca; Pneumoviridae; Pneumovirusi od Pneumoviridae;
The vaccine composition according Claim 1, wherein said composition is a homogenous mixture of the conjugated hrEGF-rP64K being free of other molecular species like hrEGF polymers or free hrEGF. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da je spomenuti sastav homogena mješavina konjugirane hrEGF- IP6AK, koja je oslobođena od ostalih vrsta molekula kao što su hrEGF polimeri ili slobodna hrEGF.
More preferred are the compounds which exhibit inhibition below 100 nM and most preferably below 50 nM. 
Više se preferiraju spojevi koji očituju mnhibiciju ispod 100 nM, a najviše preferirani ispod 50 nM.
vii) alkylsulfonyl, viii) alkylsulfinyl, ix) amino substituted with alkyl wherein said alkyl is optionally substituted with a group selected from the group consisting of monoalkylamino, dialkylamino, a saturated cyclic amino optionally substituted with alkyl, tetrahydrofuryl, morpholino, alkoxy, hydroxycarbonyl, hydroxyl and alkylthio, 
zasićena heterociklička skupina, izborno supstituirana s alkilom ili alkiloksikarbonilom, vi) alkiltio, vii) alkilsulfonil, viii) alkilsulfinil, ix) amino supstituiran s alkilom, gdje je navedeni alkil izborno supstituiran sa skupinom koju se bira iz skupine koju čine monoalkilamino, dialkilamino, zasićeni ciklički amino, izborno supstituiran s alkilom, tetrahidrofurilom, morfolino, alkoksi, hidroksikarbonilom, hidroksilom i alkiltio,
Subsequently, the pellet is resuspended in 20 mM Hepes+1 mM EDTA, pH 7.4 and homogenized with a 50-ml Dounce homogenizer and again centrifuged. 
Neposredno zatim, peleta je bila resuspendirana u 20 mM Hepes + 1 mM EDTA, pH 7.4 i homogenizirana sa 50-ml Dounce homogenizatorom i ponovno centrifugirana.
said computing and communication means are represented by one or more mobile phones of the latest generation, connected through the mobile telephone network, or the satellite or wireless telecommunication networks, said phones being able to send/receive text messages, audio/video clips, e-mails and digital photos. 
- je navedeno sredstvo za proračunavanje i sredstvo za komuniciranje (300) predstavljeno jednim ili više mobilnih telefona posljednje generacije, povezanih putem mreže mobilne telefonije ili satelita ili mreže bežičnih telekomunikacija, a navedeni su telefoni sposobni da šalju/primaju tekstualne poruke, audio/video odsječke, e-mailove i digitalne fotografije.
The method of claim 1, wherein the neurological movement disorder is Periodic Limb Movements in Sleep (PLMS). The method of claim 1, wherein the neurological movement disorder is Tourette's Syndrome. 
Inhibitor PDE7 za upotrebu u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time, da se koristi za liječenje poremećaja periodičnih pokreta udova pri spavanju (PLMS).
It is advantageous for such a rudder that, due to a flow body which is configured only locally in the area of the offset surfaces and which covers the offset surfaces, the risk of a flow breakaway can be reduced, wherein the flow body simultaneously does not influence the propulsion behavior of the ship, this being due to the relatively small dimensions thereof. 
što je u predjelu svake plohe na mjestu pomaka (18) predviđeno tijelo oko kojega prolazi strujanje (41), koje tijelo je prilagođeno, s obzirom na svoje dimenzije, dimenzijama plohe na mjestu pomaka (18) i koje tijelo pokriva plohe na mjestu pomaka (18),
Ring B is wherein R4a is a phenyl group substituted by a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, an alkylenedioxy group, 
(1) fenilna skupina, supstituirana s atomom halogena, cijano skupinom, C;.4 alkilnom skupinom, halogen-Ci.4 alkilnom skupinom, C;4 alkoksi skupinom, halogen-C,s alkoksi skupinom ili mono- ili di-C,s alkilamino skupinom; ili
The mixture of posaconazole, water or mixture of water and methanol and optionally seed crystals is then slurried, so that the posaconazole can transform to crystalline form IV. 
(1i) vode ili mješavine vode i metanola; i (111) kultiviranje kristala od kristalnog oblika TV posakonazola; i (b) dopuštanje pretvorbe posakonazola u kristalni oblik IV na temperaturi od najviše 60%C.
Solvates of the free base of Compound C 
Datum objave europske prijave patenta:
1200 scans were recorded at 4 cm-1 resolution. 
Zabilježeno je 1200 skeniranja, uz razlučivanje od 4 cm".
The crystalline form in accordance with claim 1, characterized by 
Kristalni oblik u skladu sa zahtjevom 1, karakteriziran
The DTMO is implanted at a desired location in the subject in such a way that at least a portion of the cells of the DTMO remain viable. 
Uporaba iz bilo kojeg od patentnih zahtjeva 1 - 3, naznačena time, da je najmanje jedan navedeni rekombinantni genski produkt prirodno proizveden u organu iz kojeg dermalni mikroorgan potječe.
Particularly suitable alcohols are ethanol, 1-propanol, 2-propanol (isopropanol). 
Naročito pogodni alkoholi su etanol, 1-propanol, 2-propanol (izopropanol).
Examples of suitable antipsychotic drugs for combination with the compounds in the present invention include the antipsychotics mentioned above, as well as dopamine receptor antagonists, muscarinic receptor agonists, 5HT2A receptor antagonists and 5HT2A/dopamine receptor antagonists or partial agonists (e.g., olanzepine, aripiprazole, risperidone, ziprasidone). 
Primjeri prikladnih antipsihotičkih lijekova za kombinaciju sa spojevima u prikazanom izumu uključuju gore navedene antipsihotike, jednako kao i antagoniste dopamin receptora, agoniste muskarinijskog receptora, antagoniste SHT2A receptora i antagoniste SHT2A/dopamin receptora i parcijalne agoniste (npr., olanzepin, aripiprazol, risperidon, ziprasidon).
A produced beverage is collected in the recess 33 and then guided to the guiding channel 27 underneath. 
Proizvedeni napitak se skuplja u udubljenju 33 i tada se vodi u kanal za vođenje 27 koji se nalazi ispod modula za ekstrakciju.
The antibody or an antigen-binding fragment thereof for use or pharmaceutical composition for use according to claim 12, wherein the inflammatory disease or autoimmune disease is selected from the group consisting of: inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, rheumatoid arthritis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, lupus nephritis, type I diabetes, Grave's disease, multiple sclerosis, autoimmune myocarditis, Kawasaki disease, coronary artery disease, chronic obstructive pulmonary disease, interstitial lung disease, autoimmune thyroiditis, scleroderma, systemic sclerosis, osteoarthritis, atopic dermatitis, vitiligo, graft-versus-host disease, Sjogrens's syndrome, autoimmune nephritis, Goodpasture's syndrome, chronic inflammatory demyelinating polyneuropathy, allergy, and asthma. 
Antitijelo ili njegov antigen-vezujući fragment za primjenu ili farmaceutska kompozicija za primjenu u skladu sa patentnim zahtjevom 12, gdje inflamatorna bolest ili autoimuna bolest je odabrana iz grupe koja se sastoji od: inflamatorne bolesti crijeva, Kronove bolesti, ulceroznog kolitisa, sindroma iritabilnih crijeva, reumatoidnog artritisa, psorijaze, psorijaznog artritisa, sistemskog eritemskog lupusa, lupus nefritisa, dijabetesa tipa I, Gravesove bolesti, multiple skleroze, autoimunog miokarditisa, Kawasaki-eve bolesti, koronarne arterijske bolesti, kronične opstruktivne bolesti pluća, intersticijalne bolesti pluća, autoimunog tiroiditisa, skleroderme, sistemske skleroze, osteoartritisa, atopijskog dermatitisa, vitiliga, bolesti kalem-protiv-domaćina, Sjogrens-ovog sindroma, autoimunog nefritisa, Goodpaster-ovog sindroma, kronične inflamatorne demijelinacijske polineuropatije, alergije, i astme.
The bed arrangement of claim 5, wherein the set of lying positions comprises at least three lying positions corresponding to the user lying on the back, on the stomach and on a side. 
Krevet sukladno bilo kojem od prethodnih zahtjeva, naznačen time da skup unaprijed definiranih ležećih položaja sadrži najmanje dva, a poželjno tri ležeća položaja koji odgovaraju korisniku koji leži na leđima, na trbuhu i na boku.
A power point as claimed in claim 6, characterised by comprising a timed power supply for each first light source (28). 
Točka napajanja u skladu s patentnim zahtjevom 1, naznačena time što sadrži vremenski regulirani izvor napajanja za svaki prvi izvor svjetla (28).
The fixing system according to claim 1, wherein the insulation material comprises at least one layer of at least one of a cellular material and a fibrous material. 
Sustav temeljem zahtjeva 8 pri čemu izolacijski materijal (50) uključuje barem jedan sloj celularnog i/ili vlaknastog materijala.
introducing a floweable resin in said space while impregnating the fiber mats therewith, 
- < uvođenje tekuće smole unutar navedenog prostora uz istovremeno impregniranje vlaknastih prostirača,
wrapping said film under tension at least 1.5 turns around said bale, wherein substantially no expansion of the bale of compressed bulk material occurs when the bale is removed from the chamber. 
(d) omatanje te napete folije najmanje 1.5 puta oko bale, gdje u biti ne dolazi do ekspanzije bale komprimiranog rasutog (bulk) materijala kada se bala makne iz komore.
characterized in that the racemic compound of the formula (XIII) is separated into its enantiomers, where the compound of the formula (XIII) 
(I), naznačen time što se racemski spoj s formulom (XIII) razdvaja na njegove enantiomere, gdje se spoj s formulom (XIII)
A compound of claim I for use in a method for treating, amelioration or preventing a cannabinoid receptor mediated syndrome, disorder or disease in a subject in need thereof said method comprising the step of administering to the subject an effective amount said compound. 
Spoj prema zahtjevu 1 naznačen time da je za upotrebu u postupku za liječenje, ublažavanje ili sprječavanje sindroma, poremećaja ili bolesti posredovanih sa kanabinoidnim receptorom kod subjekta kojem je to potrebno, navedeni postupak sadrži korak davanja subjektu učinkovite količine navedenog spoja.
The average molecular weight is a few million Dalton. 
Prosječna molekularna težina je nekoliko milijuna daltona.
in presence of a suitable solvent and reducing agent to form a compound of formula (I), wherein all substitutions are as defined in claim 1, optionally converting the compound of formula (I) to their pharmaceutically acceptable salts. 
2 uz prisutnost pogodnoga rastvarača 1 reduktirajućeg agensa da se formira spoj iz formule (1), pri čemu sve supstitucije kako je definirano u patentnom zahtjevu 1, (b) - opciono pretvaraju spoj iz formule (1) u njihove farmaceutski prihvatljive soli.
It is further preferred that a virus removal filtration step is carried out after step (e). 
Još je poželjno da se taj korak provodi nakon koraka (e).
A compound of claim 1 that is selected from the group consisting of: 
Spoj prema patentnom zahtjevu 1 koji je izabran iz grupe koju čine:
is selected from valylcitrulline, valyllysine, phenylalanyllysine, alanylphenylalanyllysine, and D-alanylphenylalanyllysine, CL is L is selected from and q ranges from 1 to 4, and Ab is an antibody or a fragment or derivative thereof. 
se bira između valilcitrulina, valillizina, fenilalanillizina, alanilfenilalanillizina i d-alanilfenilalanillizina, CL je [image], L se bira između [image] i [image], q je u rasponu od 1 do 4, a Ab je protutijelo ili njegov fragment ili derivat.
and when R1 is a heteroaryl, cycloalkyl, aryl-fused-cycloalkyl, heterocycloalkyl, or aryl-fused-heterocycloalkyl group, it may be substituted by one or more substituent groups as defined in claim 1. 
i kada R1 je heteroaril, cikloalkil, aril-fuzionirani-cikloalkil, heterocikloalkil, ili aril-fuzionirani-heterocikloalkil skupina, može biti supstituirana sa jednom ili više supstitucijskih skupina kako je definirano u zahtjevu 1.
In FIG. 3 the suspension element 16 is shown in the form of a mounting lug, but in alternative embodiments the suspension element 16 may comprise any suitable suspension means, for example a single hook, a double hook, a crook or any combination of these. 
Na Slici 3 ovjesni element 16 je prikazan u obliku montažne uške, ali u alternativnim izvedbama ovjesni element 16 može sadržavati bilo koje prikladno sredstvo ovješanja, na primjer jednostruku kuku, dvostruku kuku, kvaku ili bilo koju njihovu kombinaciju.
Aspect 2. The system of aspect 1 wherein the electric heater comprises a hollow tubular structure. 
Sustav (10) prema zahtjevu 1, pri čemu je električni grijač (14) električni grijač cijevastog oblika, koji obuhvaća šuplju strukturu cijevastog oblika.
Cracking furnace according to any one of the preceding claims, wherein at least a number of the burners are placed in a side-wall of the cr acking-furnace. 
Peć za cijepanje prema bilo kojem zahtjevu 7 do 13, naznačena time, da su barem neke od spirala za cijepanje raspoređene u poretku koji dozvoljava paralelni protok opskrbnog materijala kroz svaku spiralu, prilikom uporabe.
After 3 hours the reaction is concentrated in vacuo, and the residue dissolved in water. 
Nakon 3 sata reakcijsku smjesu se koncentrira u vakuumu i ostatak se otopi u vodi.
is selected from the group consisting of —H, methyl, ethyl, isopropyl, and cyclopropyl; 
Rss je izabran iz skupine koju čine -H, metil, etil, izopropil i ciklopropil;
within the first 3 hours after start of the test at the most 70% w/w of the total amount of the fumaric acid ester contained in the composition is released for oral use in treating hyperproliferative, inflammatory or autoimmune disorders by administering a daily dosage of 240 to 840 mg active substance given in one to three doses. 
unutar prva 3 sata nakon početka ispitivanja oslobodi se najviše 70% w/w ukupne količine dimetilfumarata sadržanog u sastavu, i unutar prva 4 sata nakon početka ispitivanja oslobodi se najviše 92% w/w ukupne količine dimetilfumarata.
The present invention encompasses the use of compounds of the invention for reducing the insulin resistance and hyperglycemia in any or all of the above rodent diabetes models, in humans with type 2 diabetes or other preferred metabolic-related disorders or disorders of lipid metabolism described previously, or in models based on other mammnals. 
Prikazani izum obuhvaća spojeve izuma za smanjenje inzulinske rezistencije i hiperglikemije u bilo kojem od gore navedenih modela dijabetesa glodavaca, kod ljudi s dijabetesom tipa 2 ili ostalim preferiranim metaboličkim poremećajima ili poremećajima metabolizma lipida opisanim ranije u tekstu, kao i kod modela na ostalim sisavcima.
a collapsible and expandable annular frame (12) that is configured to be collapsed to a radially collapsed state for mounting on a delivery apparatus and expanded to a radially expanded state inside the body, the frame (12) having an inflow end, an outflow end, and a longitudinal axis extending from the inflow end to the outflow end, the frame (12) comprising a plurality of struts defining a plurality of cells; and 
Protetski zalistak na bazi katetera (100) konfiguriran da bude prešan do radijalno sklopljenog stanja na balonu uređaja za isporuku koji sadrži: sklopivi i proširivi prstenasti okvir (102), konfiguriran da se sklopi u radijalno sklopljeno stanje za montiranje na aparat za dostavljanje i proširen do radijalno proširenog stanja unutar tijela;
• agitation of the mixture with the agitator at 1000-3000 rpm agitation speed in order to enable the raw materials in the obtained mixture to form a homogenous matrix, 
miješanje smjese unutar mješalice brzinom od 1.000-3.000 ob/min kako bi se omogućilo da sirovine u dobivenoj smjesi stvore homogenu matricu.
Optionally, when crystals of the orthorhombic form are available, a solution of asenapine maleate in the ethanol/water mixture can be seeded with such crystals. 
Po izboru, kada su dostupni kristali ortorombskog oblika, u otopinu asenapin maleata u smjesi etanol/voda mogu se staviti takvi kristali kao jezgre kristalizacije.
and B2 are adjacent atoms in HET1 which are independently selected from a group consisting of carbon and nitrogen; 
su susjedni atomi u HET', koji se neovisno biraju iz grupe koju čine ugljik i dušik; veza j
The solubility of the crystalline dihydrogenphosphate salt monohydrate of formula I in water has been found to be about 72 mg/mL. 
Topivost kristalnog monohidrata dihidrogenfosfatne soli formule I u vodi je oko 72 mg/mL.
selecting at least one cell-line which produces a VH domain or a VH fusion protein which binds specifically to the antigen, wherein the mammal is a mouse or a rat. 
(e) odabir barem jedne stanične linije koja proizvodi Vg domenu ili Vg fuzijski protein koji se specifično veže na antigen, pri čemu je sisavac miš ili štakor.
The resulting suspension was cooled to 0°C, filtered and washed with TFA (100mL). 
Nastala se suspenzija ohladi na 0 "C, profiltrira i ispere i TFA (40 mL).
This application claims priority to European Patent Application No. 
Datum podnošenja europske prijave patenta:
Pump 40 is a peristaltic pump having a motor 42 and a peristaltic roller mechanism 44, such as are well known and available commercially. 
Pumpa 40 je jedna peristaltična pumpa koja ima motor 42 i mehanizam 44 peristaltičkih valjaka, koji su inače poznati 1 mogu se komercijalno dobaviti.